Loading the records…
Loading the records…
HR9823, introduced July 22, 2026, would mandate coverage of Alzheimer's biomarker testing under group health plans, individual insurance, and Medicaid. The bill is in early committee stage with bipartisan cosponsorship. If enacted, it would increase utilization of diagnostic testing, benefiting clinical labs and imaging equipment providers.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill is at a procedural stage with no guaranteed passage. For investors, the primary signal is structural: Alzheimer's biomarker testing is a growing area, and a coverage mandate would accelerate adoption. $DGX and $LH offer direct exposure to the testing volume increase. $GEHC provides exposure to the imaging side. No price movement data is available to assess current market pricing, but the bill's early stage means minimal immediate impact.
On July 22, 2026, Rep. Jake Auchincloss (D-MA) introduced HR9823, the 'Alzheimer's Biomarker Testing Coverage Act,' which amends the Public Health Service Act and Social Security Act to require coverage of Alzheimer's biomarker testing. The bill has been referred to the House Committee on Energy and Commerce. It currently has one bipartisan cosponsor, Rep. Juan Ciscomani (R-AZ). The legislative path is early—committee markup, floor vote, Senate passage, and presidential action are required for enactment.
The bill does not appropriate funds; it is a coverage mandate. Insurers and state Medicaid programs must cover tests such as blood-based biomarkers, CSF analysis, and amyloid PET imaging. This would shift costs from patients to payers, increasing utilization of existing tests.
No convergence was identified with recent presidential actions, as the only relevant executive order (Jul 13, 2026) focused on chemical manufacturing regulatory relief, a separate policy domain.
Structural winners are diagnostic labs and imaging equipment manufacturers. Quest Diagnostics ($DGX) and LabCorp ($LH) are the two largest independent clinical labs offering Alzheimer's biomarker tests. GE HealthCare ($GEHC) manufactures PET/CT scanners and radiotracers used in amyloid imaging. Insurers like UnitedHealth ($UNH) face increased costs but can adjust premiums, making the net effect neutral. The bill's early stage and lack of appropriations limit near-term market impact, but bipartisan support signals potential for progress.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandate that group health plans, individual health insurance, and Medicaid programs cover Alzheimer's biomarker testing, including blood-based and CSF analysis.
Who must act
Health insurers and state Medicaid programs must reimburse for these tests.
What happens
Increased test utilization as patients gain coverage without out-of-pocket barriers, driving volume growth in clinical laboratory segments.
Stock impact
Quest Diagnostics is a leading independent clinical lab offering Alzheimer's blood tests (e.g., AD-Detect). Mandated coverage would expand the addressable patient pool, adding estimated $50M–$200M in annual revenue (less than 2% of total revenue) from neurology testing.
What the bill does
Same mandate—insurers and Medicaid must cover Alzheimer's biomarker testing.
Who must act
Health insurers and Medicaid programs.
What happens
Increased test volumes for LabCorp's Alzheimer's biomarker assays (e.g., amyloid beta, tau).
Stock impact
LabCorp offers a comprehensive Alzheimer's test menu including blood and CSF biomarkers. Full coverage would increase utilization, adding $40M–$150M in annual revenue (<1.5% of LabCorp's ~$12B revenue).
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →